Clostridium difficile infection prevention: Biotherapeutics, immunologics, and vaccines

Discovery Medicine

Volumn 13, Issue 68, 2013, Pages 75-83

  Gerding, Dale N ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; HUMAN; IMMUNOLOGY; REVIEW;

ADAPTIVE IMMUNITY; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS;

EID: 84860605588     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71(3):1608-1610, 2003.
2. Aronsson B, Granström M, Möllby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13(3):97-101, 1985.
3. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect immun 74(11):6339-6347, 2006.
4. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9(12):1044-1049, 2011.
5. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15(6):285-289, 2009.
6. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 19(3):339-350, 1985.
7. Camorlinga-Ponce M, Gamboa M, Barragan JJ, Munoz O, Fekety FR, Torres JF. Epidemiologic aspects of Clostridium difficile in a pediatric hospital and its role in diarrheal disease. Eur J Clin Microbiol 6(5):542-546, 1987.
8. Campbell RJ, Giljahn L, Machesky K, Cibulskas-White K, Lane LM, Porter K, Paulson JO, Smith FW, McDonald LC. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol 30(6):526-533, 2009.
9. Castagliuolo I, Sardina M, Brun P, DeRos C, Mastrotto C, Lovato L, Palù G. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect Immun 72(5):2827-2836, 2004.
10. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197(3):435-438, 2008.
11. Cooperstock M. Clostridium difficile in infants and children. Chapter 4. In: Clostridium difficile: Its Role in Intestinal Disease. Rolfe RD, Finegold SM (eds.). pp. 45-64. Academic Press, San Diego, California, USA, 1988.
12. Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, Kelly CP. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 41(3):237-242, 2004.
13. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT. Diminished C. difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 90(3):822-829, 1992.
14. Elixhauser A, Jhung MA. Clostridium difficile-Associated Disease in U.S. Hospitals, 1993-2005. HCUP Statistical Brief #50. Agency for Healthcare Research and Quality, Rockville, Maryland, USA, April 2008. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb50.pdf
15. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, Ryan ET. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun 75(6):2826-2832, 2007.
16. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WD, Jr. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 67(2):527-538, 1999.
17. Intercell. Announcement of first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections. Oct. 24, 2011. http://www.intercell.com/main/forvaccperts/products/clostridium-difficile-vaccine/
18. Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M, DuPont HL.. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 5(8):964-968, 2007.
19. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 166(6):1287-1294, 1992.
20. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102(1):35-40, 1992.
21. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W, Jr, Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69(2):988-995, 2001.
22. Kuehne SA, Cartman ST, Heap JT, Kelly Ml, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467(7316):711-713, 2010.
23. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342(6):390-397, 2000.
24. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357(9251):189-193, 2001.
25. Larson HE, Price AB, Borriello SP. Epidemiology of experimental enterocecitis due to Clostridium difficile. J Infect Dis 142(3):408-413, 1980.
26. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28(4):965-969, 2010.
27. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353(23):2442-2449, 2005.
28. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A.. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365(18):1693-1703, 2011.
29. Louie T, Cannon K, Byrne B, Emery J, Ward L, Krulicki W Eyben M. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection and reduces both toxin re-expression and recurrence of CDI. Annual Meeting of the Infectious Disease Society of America. Abstr# 1418. Vancouver, B.C., Canada, Oct. 24, 2010.
30. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362(3):197-205, 2010.
31. Lyerly DM, Saum KE, Macdonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect immun 47(2):349-352, 1985.
32. Lyerly DM, Frey SM, Wilkins TD. Vaccination against lethal Clostridium difficile enteritis with a nontoxigenic recombinant peptide of toxin A. Curr Microbiol 21():29-33, 1990.
33. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. Toxin B is essential for virulence of Clostridium difficile. Nature 458(7242):1176-1179, 2009.
34. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353(23):2433-2441, 2005.
35. Merida V, Moerman J, Colaert J, Lemmens P, Vandepitte J. Significance of Clostridium difficile and its cytotoxin in children. Eur J Pediatr 144(5):494-496, 1986.
36. Merrigan MM, Sambol SP, Johnson S, Gerding DN. Prevention of fatal Clostridium-difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis 188(12):1922-1927, 2003.
37. Merrigan MM, Sambol SP, Johnson S, Gerding DN. New Approach to the Management of Clostridium difficile Infection: Colonization with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 33(Supp 1):S46-S50, 2009.
38. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 32(4):387-390, 2011.
39. Miyazaki S, Matsunaga T, Kawasaki K, Kobayashi I, Tada H, Yamaguchi K, Goto S. Separate isolation of C. difficile spores and vegetative cells from the feces of newborn infants. Microbiol Immunol 36(2):131-138, 1992.
40. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79(6):2295-2302, 2011.
41. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes 2(3):145-158, 2011.
42. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 65(7):2941-2949, 1997.
43. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186(12):1781-1789, 2002.
44. Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6(1):51-53, 1987.
45. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351(9103):633-636, 1998.
46. Siddiqui F, O'Connor JR, Nagaro K, Adam Cheknis, Sambol SP, Vedantam G, Gerding DN, Johnson S. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive Clostridium difficile but does not prevent colonization. J Infect Dis, epub ahead of print, Nov. 28, 2011.
47. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128(3):764-770, 2005.
48. Stark PL, Lee A, Parsonage BD. Colonization of the large bowel by Clostridium difficile in healthy infants: Quantitative study. Infect Immun 35(3):895-899, 1982.
49. Sutphen JL, Grand RJ, Flores A, Chang TW, Bartlett JG. Chronic diarrhea associated with Clostridium difficile in children. Am J Dis Children 137(3):275-278, 1983.
50. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 81():429-433, 1974.
51. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 63(12):4619-4627, 1995.
52. Tullus K, Aronsson B, Marcus S, Mollby R. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis 8(5):390-393, 1989.
53. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1(8648):1156-1160, 1989.
54. Villano SA, Tatarowicz W, Seiberling M, Gerding DN, Gomez A, Monnot-Chase E. Phase I evaluation of an oral suspension of VP 20621, spores of a non-toxigenic C. difficile strain (NTCD) in healthy older subjects pretreated with oral vancomycin [abstract]. Proceedings of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr# F1-2127b. Boston, Massachusetts, USA, Sep. 12-15, 2010.
55. Viscidi RP, Bartlett JG. Antibiotic-associated pseudomembranous colitis in children. Pediatrics 67(3):381-386, 1981.
56. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 148(1):93-100, 1983.
57. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 67(5):2145-2152, 1999a.
58. Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun 67(10):5124-5132, 1999b.
59. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis 147(4):733-736, 1983.